An overview of the new guidance relating to the use of DOACs for cancer associated thrombosis, for patients at extremes of body weight, and the use of DOACs in paediatrics. Discussion around the best choice of DOAC for women of childbearing age to minimise bleeding risk. An update on NICE guidance for the use of Andexanet alfa and a discussion on its place in the management of bleeding.